Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

<p>Abstract</p> <p>Background</p> <p>Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m<sup>2 </sup>and 100 mg/m<sup>2</sup>) or weekly regimens (35–40 mg/m<sup>2</sup>). The pharmacokinetics and radios...

Full description

Bibliographic Details
Main Authors:	Kristensen Vessela, Aamdal Steinar, Andersen Anders, Fr Brunsvig Paal, Olsen Harald
Format:	Article
Language:	English
Published:	BMC 2007-10-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/7/197

Similar Items

Population pharmacokinetics of docetaxel in patients with solid tumors
by: XI Xin, et al.
Published: (2022-11-01)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
by: Wenchao Yang, et al.
Published: (2022-08-01)

Press-release Combination treatment with Vargatef® and docetaxel contributes to statistically significant tumor reduction in patients with progressive adenocarcinoma of the lung in comparison with docetaxel in monotherapy
by: - -
Published: (2015-09-01)

Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use
by: Abdelrahman M. Elhusseiny, et al.
Published: (2019-12-01)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
by: Andreas Venizelos, et al.
Published: (2022-08-01)

Feasibility and Response of Concurrent Weekly Docetaxel with Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
by: Jomon Raphael C, et al.
Published: (2015-03-01)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01)

Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
by: Jabir, Rafid, et al.
Published: (2014)

Undifferentiated prostate cancer treated with docetaxel
by: Masaki Kobayashi, et al.
Published: (2020-07-01)

Effect of surface ligand density on cytotoxicity and pharmacokinetic profile of docetaxel loaded liposomes
by: Chun Chu, et al.
Published: (2016-10-01)

Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel
by: Somayeh Taymouri, et al.
Published: (2018-01-01)

Severe acral erythrodysesthesia and docetaxel
by: Justin Bagorane, et al.
Published: (2021-04-01)

Docetaxel-related interstitial pneumonitis
by: Wang CJ, et al.
Published: (2015-12-01)

Evaluation of the efficacy and feasibility of concurrent weekly docetaxel-nedaplatin and hypo-fractionated radiotherapy in atypical histologic subtypes of primary and metastatic mediastinal malignancies
by: FanJun Meng, et al.
Published: (2022-10-01)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
by: Xi-Lei Zhou, et al.
Published: (2021-05-01)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
by: Victor Omoboyede, et al.
Published: (2023-04-01)

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
by: Rafiei P, et al.
Published: (2017-01-01)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
by: Vermunt M, et al.
Published: (2021-01-01)

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters
by: Kuniaki Katsui, et al.
Published: (2020-07-01)

Biodistribution of samarium-153-EDTMP in rats treated with docetaxel Biodistribuição de EDTMP-153-samário em ratos tratados com docetaxel
by: Arthur Villarim Neto, et al.
Published: (2009-02-01)

Docetaxel-Induced Nail Bed Purpura
by: Arunachalam Narayanan, et al.
Published: (2023-07-01)

Docetaxel-induced radiation recall dermatitis
by: EG Kandemir, et al.
Published: (2005-01-01)

Grover disease associated with docetaxel chemotherapy
by: Shawn Afvari, BS, et al.
Published: (2022-11-01)

Solubilization Methods for Paclitaxel and Docetaxel: An Overview
by: Fariba Pourkarim, et al.
Published: (2022-04-01)

Docetaxel Retinopathy: A Case Report
by: Sylvia Nghiem-Buffet, et al.
Published: (2017-01-01)

Review of docetaxel in the treatment of gastric cancer
by: Eric D Tetzlaff, et al.
Published: (2008-09-01)

Severe Photo Toxicity Recalled by Docetaxel
by: Emma K. Johansson, et al.
Published: (2018-11-01)

Adverse reactions to docetaxel: an active survey
by: Leandro Cabral Pereira, et al.
Published: (2015-09-01)

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer
by: Thomas Heineman, et al.
Published: (2021-09-01)

The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial
by: Yanrong Luo MD, et al.
Published: (2022-06-01)

Maximum tolerated dose and toxicity evaluation of orally administered docetaxel granule in mice
by: Xiaowei Dong, et al.
Published: (2024-06-01)

Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and Bisphosphonate
by: Masaya Ishibashi, et al.
Published: (2012-01-01)

Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer
by: Yuxiang Ma, et al.
Published: (2021-04-01)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
by: Houbao Huang, et al.
Published: (2020-08-01)

ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
by: Anand Patil, et al.
Published: (2021-07-01)

Novel Docetaxel-Loaded Micelles Based on all-trans-Retinoic Acid: Preparation and Pharmacokinetic Study in Rats
by: Ya-Ni Yang, et al.
Published: (2022-09-01)

FEASIBILITY OF INDUCTION DOCETAXEL, CISPLATIN, 5-FLUOROURACIL, CETUXIMAB (TPF-C) FOLLOWED BY CONCURRENT CETUXIMAB RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
by: Nikolaos eCharalambakis, et al.
Published: (2013-01-01)

Docetaxel Distribution Following Intraperitoneal Administration in Mice
by: Payam Zahedi, et al.
Published: (2011-02-01)

The effect of docetaxel on retinal pigment epithelial cells
by: Jialin Li, et al.
Published: (2022-01-01)

Role of docetaxel in the treatment of advanced gastric carcinoma
by: Mario Scartozzi, et al.
Published: (2009-03-01)